Maria Cantor, who led corporate affairs for ARIAD Pharmaceuticals, has decamped to Dutch gene therapy developer uniQure N.V. as senior VP of IR and communications, based in Lexington, Mass.
The Netherlands-based uniQure, publicly traded on the Nasdaq exchange, is developing therapies for diseases of the central nervous system, liver/metabolic, and cardiovascular diseases. CEO Dan Soland praised Cantor's experience "defining the long-term value proposition" for sucessful companies in the sector.
Cantor earlier directed corporate and product communications at Genzyme and handled marketing, PR and communications at the St. Elizabeth Medical Center in Boston and Optima Healthcare in New Hampshire.
At uniQure, she serves on the company's senior management team.
Why CEO visibility is no longer optional as a communications tactic.
The “waiting period” that was once set aside for CEOs to develop their strategies before facing media scrutiny may be better used for corporate comms leaders get to know their CEO and what his or her short-term priorities will be.
Senior-most communications executives in the Fortune 500 earned between $50,000 and $100,000 more this year than they did two years ago, according to a recent survey of chief communications officers.
